Access the full text.
Sign up today, get DeepDyve free for 14 days.
DJ Slamon, B Leyland-Jones, S Shak (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med, 344
SK Mohsin, HL Weiss, MC Gutierrez (2005)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancersJ Clin Oncol, 23
M. Scaltriti, F. Rojo, A. Ocaña, J. Anido, M. Guzman, J. Cortés, S. Cosimo, X. Matías-Guiu, S. Cajal, J. Arribas, J. Baselga (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.Journal of the National Cancer Institute, 99 8
S. Mohsin, H. Weiss, M. Gutiérrez, G. Chamness, R. Schiff, M. DiGiovanna, Chun-xia Wang, S. Hilsenbeck, C. Osborne, D. Allred, R. Elledge, Jenny Chang (2005)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancersNature Clinical Practice Oncology, 2
E. Perez, E. Romond, V. Suman, Jong-Hyeon Jeong, N. Davidson, C. Geyer, S. Martino, E. Mamounas, P. Kauffman, N. Wolmark, Ncctg, Nsabp (2007)
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancerJournal of Clinical Oncology, 25
F. André, F. André, C. Mazouni, C. Liedtke, S. Kau, Debby Frye, Marjorie Green, A. González-Angulo, W. Symmans, G. Hortobagyi, L. Pusztai (2008)
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancerBreast Cancer Research and Treatment, 108
K. Blackwell, H. Burstein, A. Storniolo, H. Rugo, G. Sledge, M. Koehler, C. Ellis, M. Casey, S. Vukelja, J. Bischoff, J. Baselga, J. O’Shaughnessy (2010)
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
A. Buzdar, N. Ibrahim, D. Francis, D. Booser, E. Thomas, R. Theriault, L. Pusztai, Marjorie Green, B. Arun, S. Giordano, M. Cristofanilli, D. Frye, T. Smith, K. Hunt, S. Singletary, A. Sahin, M. Ewer, T. Buchholz, D. Berry, G. Hortobagyi (2005)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 16
R. Nahta, Dihua Yu, M. Hung, G. Hortobagyi, F. Esteva (2006)
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancerNature Clinical Practice Oncology, 3
H. Joensuu, P. Kellokumpu-Lehtinen, P. Bono, T. Alanko, V. Kataja, R. Asola, T. Utriainen, R. Kokko, A. Hemminki, M. Tarkkanen, T. Turpeenniemi‐Hujanen, S. Jyrkkiö, M. Flander, L. Helle, S. Ingalsuo, Kaisu Johansson, A. Jääskeläinen, M. Pajunen, Mervi Rauhala, J. Kaleva-Kerola, T. Salminen, M. Leinonen, I. Elomaa, J. Isola (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.The New England journal of medicine, 354 8
S. Johnston, M. Trudeau, B. Kaufman, H. Boussen, K. Blackwell, P. LoRusso, D. Lombardi, S. Ahmed, D. Citrin, M. Desilvio, Jennifer Harris, R. Westlund, V. Salazar, T. Zaks, N. Spector (2008)
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 7
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
Freddie Hamdy, Jenny Donovan, Athene, Chris Metcalfe, M. Davis, R. Martin, Bollina J., Andrew Doble, Alan Doherty, Gillatt, Gnanapragasam David, O. Hughes, Howard, A. Paul, E. Paez, P. Powell, M. Mason, J. Oxley, J. Lane, M. Davis, E. Turner, G. Young, E. Walsh, R. Bryant, P. Bollina, D. Gillatt, V. Gnanapragasam, O. Hughes, R. Kockelbergh, H. Kynaston, E. Paez, P. Powell, D. Rosario, E. Rowe, M. Mason, T. Peters, J. Oxley, N. Williams, J. Staffurth, D. Neal (2023)
The n e w e n g l a n d j o u r n a l of m e d i c i n e
Charles Geyer, J. Forster, D. Lindquist, Stephen Chan, C. Romieu, T. Pieńkowski, A. Jagiełło-Gruszfeld, J. Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, M. Campone, Neville Davidson, Mark Berger, C. Oliva, S. Rubin, S. Stein, David Cameron (2006)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.The New England journal of medicine, 355 26
G. Konecny, M. Pegram, N. Venkatesan, R. Finn, Guorong Yang, M. Rahmeh, M. Untch, D. Rusnak, G. Spehar, R. Mullin, B. Keith, T. Gilmer, M. Berger, K. Podratz, D. Slamon (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.Cancer research, 66 3
I. Smith, M. Procter, R. Gelber, S. Guillaume, A. Feyereislova, M. Dowsett, A. Goldhirsch, M. Untch, G. Mariani, J. Baselga, M. Kaufmann, D. Cameron, R. Bell, J. Bergh, R. Coleman, A. Wardley, N. Harbeck, R. López, P. Mallmann, K. Gelmon, N. Wilcken, E. Wist, P. Rovira, M. Piccart-Gebhart (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialThe Lancet, 369
M. Cristofanilli, A. González-Angulo, N. Sneige, S. Kau, K. Broglio, R. Theriault, V. Valero, A. Buzdar, H. Kuerer, T. Buchholz, G. Hortobagyi (2005)
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 1
Curr Breast Cancer Rep (2011) 3:1–3 DOI 10.1007/s12609-010-0032-2 CLINICAL TRIAL REPORT Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez) Antonio C. Wolff Published online: 18 December 2010 Springer Science+Business Media, LLC 2010 Rating outcome of patients with early-stage HER2-positive disease treated with adjuvant trastuzumab may now surpass that of �� Of major importance patients whose tumors lack over-expression or gene amplification. Approximately 15% of patients with HER2-positive Introduction disease still recur within 5 years despite adjuvant trastuzu- mab. Mechanisms of resistance may include heterodimer It has been close to 25 years since the first reports on the signaling of other HER proteins, activation of the p95 association between amplification of the human epidermal truncated form of HER2, and cross-talk with other receptor growth receptor 2 gene (HER2) and inferior outcomes in pathways [6]. p95HER2 expression is observed in approx- breast cancer [1]. HER2 was soon recognized as a strong imately 25% of HER2-positive tumors, and intrinsic prognostic marker for poor outcome, and assays to detect activation of the kinase domain may explain the inferior gene amplification and protein over-expression in formalin- clinical outcome [7]. New therapies are under
Current Breast Cancer Reports – Springer Journals
Published: Dec 18, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.